It ain't what you do, it's the way you do it: five golden rules for transforming prostate-specific antigen screening

Andrew Vickers; Sigrid Carlsson; Vincent Laudone; Hans Lilja

doi:10.1016/j.eururo.2013.12.049

It ain't what you do, it's the way you do it: five golden rules for transforming prostate-specific antigen screening

Eur Urol. 2014 Aug;66(2):188-90. doi: 10.1016/j.eururo.2013.12.049. Epub 2014 Jan 4.

Authors

Andrew Vickers¹, Sigrid Carlsson², Vincent Laudone³, Hans Lilja⁴

Affiliations

¹ Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. Electronic address: vickersa@mskcc.org.
² Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Department of Urology, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden.
³ Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
⁴ Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Departments Medicine and Laboratory Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.

PMID: 24411991
DOI: 10.1016/j.eururo.2013.12.049

Abstract

The benefit-harm ratio of PSA screening can be dramatically improved by avoiding screening, biopsy and treatment in men who are unlikely to benefit, and by referring men that do need treatment to high volume centers.

Publication types

Editorial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Biopsy
Early Detection of Cancer / methods*
Early Detection of Cancer / standards
Hospitals, High-Volume
Humans
Informed Consent
Male
Prostate / pathology*
Prostate-Specific Antigen / blood*
Prostatectomy
Prostatic Neoplasms / blood*
Prostatic Neoplasms / pathology*
Prostatic Neoplasms / surgery
Risk Assessment

Substances

Prostate-Specific Antigen

Abstract

Publication types

MeSH terms

Substances

Grants and funding